Pre-made Abituzumab benchmark antibody ( Whole mAb, anti-ITGAV therapeutic antibody, Anti-CD51/MSK8/VNRA/VTNR Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-003
Pre-Made Abituzumab biosimilar, Whole mAb, Anti-ITGAV Antibody: Anti-CD51/MSK8/VNRA/VTNR therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Abituzumab biosimilar, Whole mAb, Anti-ITGAV Antibody: Anti-CD51/MSK8/VNRA/VTNR therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Colorectal cancer;Systemic scleroderma|
|Conditions Discontinued||Ovarian cancer;Prostate cancer;Solid tumours|